The company hails a partial clinical trial win as the way in to a new use for Hetlioz, but the stock markets are less convinced.
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
Investors had been awaiting an update on voxelotor with trepidation, but a lenient FDA has lit up the company’s Ash.
Amid a frenzy of BCMA-targeting multiple myeloma therapies Bluebird Bio’s bb21217 falls neatly into the Goldilocks zone.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.